Amarin Corp Plc (AMRN)

[retinadoc]

http://www.visionmonday.com/latest-news/article/shire-reports-sales-growth-of-6-percent-in-q2-as-xiidra-hits-100-million-in-sales/

DES is big money and a reoccurring revenue stream. Unlike Reduce-it this would be a very easy/quick study for Amarin to do. This is Zip's expertise, but the results of tear film production and composition are quantifiable. I would think all you would need is 6 months at most on Vascepa to see changes.

I hope someone at AMRN is mining the Reduce-it data for diabetic retinopathy, macular degeneration, and vein occlusion data. The association of mac degeneration with C- reactive protein is absolute, and is likely serving as an inflammatory marker as trigs did in reduce-it.